These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2973361)

  • 21. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
    Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
    Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.
    Majolino I; Corradini P; Scimè R; Santoro A; Tarella C; Cavallaro AM; Palumbo A; Indovina A; Caracciolo D; Boccadoro M; Marcenò R; Pileri A
    Bone Marrow Transplant; 1998 Sep; 22(5):449-55. PubMed ID: 9733268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.
    Zomas A; Stefanoudaki K; Fisfis M; Papadaki T; Mehta J
    Bone Marrow Transplant; 1998 Jun; 21(11):1163-5. PubMed ID: 9645583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic bone marrow transplantation in multiple myeloma using HLA-compatible sibling donors--an EBMT Registry Study.
    Gahrton G; Tura S; Ljungman P; Belanger B; Brandt L; Cavo M; Chapuis B; De Laurenzi A; de Witte T; Facon T
    Bone Marrow Transplant; 1991; 7 Suppl 2():32. PubMed ID: 1878706
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
    Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
    Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of MLC for BMT with serological HLA-identical related and unrelated donors.
    Bonfichi M; Bernasconi P; Brera C; Boni M; Caldera C; Campagnoli C; Alessandrino EP; Bernasconi C
    Bone Marrow Transplant; 1993; 11 Suppl 1():28-30. PubMed ID: 8448540
    [No Abstract]   [Full Text] [Related]  

  • 31. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic bone marrow transplantation versus chemotherapy for childhood acute lymphoblastic leukaemia in second remission.
    Bacigalupo A; Van Lint MT; Frassoni F; Occhini D; Pittaluga PA; Comelli A; Dini G; Massimo L; Marmont AM
    Bone Marrow Transplant; 1986 May; 1(1):75-80. PubMed ID: 3332122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
    Yee GC; McGuire TR
    Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic bone marrow transplantation for multiple myeloma.
    Ballester OF
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
    Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
    Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Allogeneic bone marrow transplantation in children from related donors other than HLA-identical siblings].
    Morimoto T; Hattori K; Yabe H; Yabe M; Hinohara T; Shimizu T; Matsumoto M; Hagihara M; Tsuji K; Kato S
    Rinsho Ketsueki; 1998 Sep; 39(9):631-9. PubMed ID: 9796395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: a comparative matched cohort study.
    Fleming DR; Henslee-Downey PJ; Romond EH; Harder EJ; Marciniak E; Munn RK; Messino MJ; Macdonald JS; Bishop M; Rayens MK; Thompson JS; Foon KA
    Bone Marrow Transplant; 1996 Jun; 17(6):917-22. PubMed ID: 8807094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
    Gesundheit B; Shapira MY; Ackerstein A; Resnik IB; Bitan M; Or R
    Acta Haematol; 2007; 117(2):119-21. PubMed ID: 17135719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen].
    Kmonícek M; Jebavý L; Lánská M; Zák P; Malý J; Maisnar V
    Vnitr Lek; 2000 Jul; 46(7):377-83. PubMed ID: 15635796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation.
    van der Griend R; Verdonck LF; Petersen EJ; Veenhuizen P; Bloem AC; Lokhorst HM
    Bone Marrow Transplant; 1999 Jan; 23(2):195-7. PubMed ID: 10197809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.